Proteostasis Therapeutics Inc.

05/13/2021 | Press release | Distributed by Public on 05/14/2021 09:59

Demonstrated lead program YMTX-7739 inhibits novel target in healthy volunteers at levels consistent with improved motor function in an animal model of Parkinson's disease[...]

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.